诚意药业(603811) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥138,627,619.85, representing a decrease of 12.30% compared to the same period last year[5] - Net profit attributable to shareholders was ¥23,348,120.24, down 37.86% year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥21,834,417.67, a decline of 41.34% compared to the previous year[5] - Basic and diluted earnings per share were both ¥0.07, reflecting a decrease of 36.36% from the same quarter last year[6] - Total revenue for the first three quarters of 2023 was CNY 459,487,529.22, a decrease of 3.1% compared to CNY 476,221,538.79 in the same period of 2022[20] - Operating costs for the first three quarters of 2023 were CNY 393,013,923.73, slightly down from CNY 393,895,293.76 in 2022[20] - Net profit for Q3 2023 was CNY 113,504,894.78, an increase of 10.0% from CNY 102,486,877.63 in Q3 2022[21] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.35, up from CNY 0.31 in Q3 2022[23] Assets and Liabilities - Total assets increased to ¥1,833,980,462.20, marking a growth of 6.68% from the end of the previous year[6] - Total assets as of Q3 2023 amounted to CNY 1,833,980,462.20, compared to CNY 1,719,093,524.95 in Q3 2022, reflecting a growth of 6.7%[19] - Total liabilities increased to CNY 685,911,170.65 in Q3 2023 from CNY 628,161,634.93 in Q3 2022, marking a rise of 9.2%[19] - Shareholders' equity reached CNY 1,148,069,291.55 in Q3 2023, compared to CNY 1,090,931,890.02 in Q3 2022, indicating an increase of 5.2%[19] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥124,610,776.23, an increase of 16.75%[5] - In the first three quarters of 2023, the net cash flow from operating activities was ¥124,610,776.23, an increase of 16.5% compared to ¥106,729,566.50 in the same period of 2022[24] - Total cash inflow from operating activities was ¥492,891,005.54, while cash outflow was ¥368,280,229.31, resulting in a net cash inflow of ¥124,610,776.23[24] - Cash flow from investing activities showed a net outflow of ¥45,109,147.48, a significant improvement from a net outflow of ¥187,319,159.87 in the previous year[25] - Cash inflow from financing activities was ¥250,319,618.00, while cash outflow was ¥234,883,799.29, leading to a net cash inflow of ¥15,435,818.71[25] - The company reported a cash and cash equivalents balance of ¥308,365,117.60 at the end of the third quarter, up from ¥195,984,125.00 at the end of the same period last year[25] Investments and Expenses - The company reported a significant increase in short-term borrowings by 148.55%, primarily due to increased bank loans[10] - The company's investment income for the year-to-date rose by 42.06%, indicating improved returns from external investment projects[10] - Research and development expenses for Q3 2023 were CNY 35,398,105.34, slightly up from CNY 35,003,808.66 in Q3 2022[21] - The company reported a financial expense of CNY 5,219,582.71 in Q3 2023, significantly higher than CNY 1,585,591.42 in Q3 2022[21] - The company invested ¥56,362,447.48 in fixed assets and intangible assets during the third quarter, a decrease from ¥198,789,078.37 in the same quarter of the previous year[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,800[13] - The largest shareholder, Yan Yiyi, holds 23.58% of the shares, totaling 77,192,080 shares[14] Other Financial Metrics - The weighted average return on equity decreased to 2.12%, down 1.59 percentage points from the previous year[6] - The company experienced a 54.34% increase in minority interests, mainly due to capital injections from minority shareholders in a subsidiary[10] - The company received ¥14,029,107.02 in tax refunds, a significant increase from ¥648,018.86 in the previous year[24] - The company raised ¥2,100,000.00 from minority shareholders as part of its financing activities[25] - The company’s cash flow from operating activities was positively impacted by a reduction in tax payments, which decreased from ¥49,335,000.04 to ¥35,920,189.47[24] - The company experienced a foreign exchange gain of ¥17,046.68 during the third quarter[25]